期刊文献+

阿立哌唑对女性首发和复发精神分裂症甲状腺激素、泌乳素的影响 被引量:10

Treatment effects of aripiprazole on thyroid hormones and prolactin in female schizophrenia
下载PDF
导出
摘要 目的探讨阿立哌唑对女性精神分裂症住院患者甲状腺激素、泌乳素的影响及首发、复发病例的差异。方法随机抽取女性精神分裂症患者67例(首发26例,复发41例),均用阿立哌唑治疗,于治疗前和治疗2、4、8周末进行抽血检验甲状腺激素和泌乳素。结果阿立哌唑治疗2周末时,血清甲状腺素(T4)、血清泌乳素(PRL)有显著性差异。结论阿立哌唑短期使用(2周末)时可以降低患者血清甲状腺素(T4)、血清泌乳素(PRL)水平,而4-8周时则无明显差异;对三碘甲腺原氨酸(T3)、游离三碘甲腺原氨酸(FT3)、游离甲状腺素(FT4)、促甲状腺素(TSH)无明显差异;首发与复发病例无明显差异。 Objective: To explore effects on thyroid hormones and prolactin by aripiprazole in initial and recurrent female schizophrenia. Methods: 67 radomly chosen cases(26 were initial and 41 were recurrent cases) of female schizophrenia were treated with aripiprazole. Thyroid hormones and prolactin (PRL)were measured before and after 2,4,8 weeks of treatment respectively. Results: Serum thyroid hormone (T4) and prolactin(PRL) were significantly lower after 2 weeks of treatment. Conclusion : Serum thyroid hormone (T4) and prolactin(PRL) were lower after short period (2 weeks) of treatment, while remain no difference after long term treatment(4 and 8 weeks). Triiodothyronine (T3) , free triiodothyronine (FI3), free serum thyroid hormone(FF4) and thyroid stimulating hormone (TSH) all remained unchanged. Initial and recurrent cases showed no difference.
出处 《上海精神医学》 2007年第3期163-164,155,共3页 Shanghai Archives of Psychiatry
基金 金市科字2006-3-088基金项目
关键词 阿立哌唑 精神分裂症 女性 首发 复发 甲状腺激素 泌乳素 Aripiprazole Schizophrenia Female Initial Recurrent Thyroid hormones Prolactin
  • 相关文献

参考文献6

  • 1黄文武,姜德国.抗精神病新药阿立哌唑[J].上海精神医学,2003,15(5):307-308. 被引量:153
  • 2Kaue JM,Carson WH,Saha AR,et al.Efficacy and safety of aripiprazole and hatopefidol versus placebo inpatients with schizophrenia and sehizoaffective disorder.J Clin Psychiatry,2002 Sep,63(9):763-771
  • 3Marder SR,MeQuade RD,Stock E,et al.Aripiprazole in the treatment of schizophrenia:safety and tolerability in short-term placebo-controlled trims.Sehizophr Res,2003Jun,61:123-136
  • 4Yokoi F,Grunder G,Biziere K,et al.Dopamine D2 and D3receptor occupancy in normal humans treated with the antipsychotie drug aripiprazole(OPC 14597):a study using positron emission tomography (PET)and raclopride.Neuropsychopharmacology,2002;27(2):248-259
  • 5Inoue A,Seto M,Sugita S,et al.Differential effects on D2 dopamine receptor and prolaetin gene expression by haloperidol and aripiprazole in the rat pituitary.Brain Res,1998 apr,55:285-292
  • 6Himse T,Uwahedo Y,Yamada S,et al.Efficacy and favorable side-effect profile of aripiprazole determined in rat with apomorphineinduced stereotype,catalepsy.and ptosis induction.Int J Neumpsyehophann,2000,3(Suppl):S131-136

二级参考文献15

  • 1[1]Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl] butyloxy)-3,4-dihydro-2 ( 1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther, 1995 Jul, 274( 1 ) :329 ~ 336
  • 2[2]Fleishhacker WW. New developments in the pharmacotherapy of schizophrenia. J Neural transm Suppl, 2003, 105 ~ 117
  • 3[3]Oshiro Y, Sato S, Kurahashi N, et al. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[ 4-( 4-phenyl-1-piperazinyl ) butoxy ]-3, 4-dthydro-2 (1H)-quinolinone derivatives. J Med Chem, 1998 Feb, 41 : 658 ~667
  • 4[4]Matsubayashi H, Amano T, Sasa M. Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra. Psychopharmacolgy (Berl), 1999 Sep, 146(2) : 139 ~ 143
  • 5[5]Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropschopharmacolgy, 1999 Jun, 20(6) : 612~627
  • 6[6]Inoue A, Seto M, Sugita S, et al. differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat ptiuitary. Brain Res Mol Brain Res, 1998 apr, 55 : 285 ~292
  • 7[7]Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.Neuropsychopharmacology, 2003 May
  • 8[8]Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT ( 1 A) receptor. Eur J Pharmacol, 2002 Apr 26,441(3) : 137 ~140
  • 9[9]Goodnick P J, Jerry JM. aripiprazole: profile on efficacy and safety.Expert Opin Pharmacother, 2002 Dec, 3(12) : 1773 ~ 1781
  • 10[10]Stahl SM. dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J Clin Psychiatry, 2001 Nov, 62 (11 ) : 841 ~ 842

共引文献152

同被引文献60

引证文献10

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部